Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis

Masanao Nakamura; Takeshi Yamamura; Keiko Maeda; Tsunaki Sawada; Yasuyuki Mizutani; Eri Ishikawa; Ayako Ohashi; Go Kajikawa; Kazuhiro Furukawa; Eizaburo Ohno; Takashi Honda; Hiroki Kawashima; Masatoshi Ishigami; Mitsuhiro Fujishiro

doi:10.2169/internalmedicine.5302-20

Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis

Masanao Nakamura
, Takeshi Yamamura
, Keiko Maeda
, Tsunaki Sawada
, Yasuyuki Mizutani
, Eri Ishikawa
, Ayako Ohashi
, Go Kajikawa
, Kazuhiro Furukawa
, Eizaburo Ohno
, Takashi Honda
, Hiroki Kawashima
, Masatoshi Ishigami
, Mitsuhiro Fujishiro

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

8 被引用数 (Scopus)

抄録

Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20- year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.

本文言語	英語
ページ（範囲）	3009-3014
ページ数	6
ジャーナル	Internal Medicine
巻	59
号	23
DOI	https://doi.org/10.2169/internalmedicine.5302-20
出版ステータス	出版済み - 01-12-2020
外部発表	はい

All Science Journal Classification (ASJC) codes

内科学

文献へのアクセス

10.2169/internalmedicine.5302-20

他のファイルとリンク

フィンガープリント

「Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Nakamura, M., Yamamura, T., Maeda, K., Sawada, T., Mizutani, Y., Ishikawa, E., Ohashi, A., Kajikawa, G., Furukawa, K., Ohno, E., Honda, T., Kawashima, H., Ishigami, M., & Fujishiro, M. (2020). Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis. Internal Medicine, 59(23), 3009-3014. https://doi.org/10.2169/internalmedicine.5302-20

@article{b20efb392a714055804bbaf080bc95ec,

title = "Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis",

abstract = "Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20- year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.",

author = "Masanao Nakamura and Takeshi Yamamura and Keiko Maeda and Tsunaki Sawada and Yasuyuki Mizutani and Eri Ishikawa and Ayako Ohashi and Go Kajikawa and Kazuhiro Furukawa and Eizaburo Ohno and Takashi Honda and Hiroki Kawashima and Masatoshi Ishigami and Mitsuhiro Fujishiro",

note = "Publisher Copyright: {\textcopyright} 2020 The Japanese Society of Internal Medicine.",

year = "2020",

month = dec,

day = "1",

doi = "10.2169/internalmedicine.5302-20",

language = "English",

volume = "59",

pages = "3009--3014",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "23",

}

Nakamura, M, Yamamura, T, Maeda, K, Sawada, T, Mizutani, Y, Ishikawa, E, Ohashi, A, Kajikawa, G, Furukawa, K, Ohno, E, Honda, T, Kawashima, H, Ishigami, M & Fujishiro, M 2020, 'Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis', Internal Medicine, vol. 59, no. 23, pp. 3009-3014. https://doi.org/10.2169/internalmedicine.5302-20

TY - JOUR

T1 - Refractory ulcerative colitis improved by scheduled combination therapy of vedolizumab and granulocyte and monocyte adsorptive apheresis

AU - Nakamura, Masanao

AU - Yamamura, Takeshi

AU - Maeda, Keiko

AU - Sawada, Tsunaki

AU - Mizutani, Yasuyuki

AU - Ishikawa, Eri

AU - Ohashi, Ayako

AU - Kajikawa, Go

AU - Furukawa, Kazuhiro

AU - Ohno, Eizaburo

AU - Honda, Takashi

AU - Kawashima, Hiroki

AU - Ishigami, Masatoshi

AU - Fujishiro, Mitsuhiro

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20- year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.

AB - Granulocyte and monocyte adsorptive apheresis (GMA) is occasionally introduced as an alternative combination therapy after loss of response to biologics in ulcerative colitis (UC) patients. However, there have been no reports of the concomitant use of vedolizumab (VDZ) and GMA for the initial induction of UC. A 20- year-old man with refractory UC was admitted for recrudescence. VDZ monotherapy had previously been introduced but was ineffective. Therefore, he received scheduled combination of VDZ and GMA and achieved clinical remission. The combination of two different approaches to inhibit the migration of leukocytes into the inflamed tissue led to satisfactory clinical outcomes.

UR - https://www.scopus.com/pages/publications/85097210663

UR - https://www.scopus.com/pages/publications/85097210663#tab=citedBy

U2 - 10.2169/internalmedicine.5302-20

DO - 10.2169/internalmedicine.5302-20

M3 - Article

C2 - 32727993

AN - SCOPUS:85097210663

SN - 0918-2918

VL - 59

SP - 3009

EP - 3014

JO - Internal Medicine

JF - Internal Medicine

IS - 23

ER -